Seres Therapeutics (MCRB) Price to Sales (2016 - 2026)

Seres Therapeutics has disclosed Price to Sales across 10 years of filings, most recently posting 105.35 for Q2 2026.

• In Q2 2026, Price to Sales changed N/A year-over-year to 105.35; the TTM figure through Jun 2026 stood at 41.18 (changed N/A YoY), while the FY2025 annual figure was 180.23, changed N/A from the prior year.
• Price to Sales came in at 105.35 for Q2 2026 at Seres Therapeutics, down from 237.66 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 1375.06 in Q1 2023 to a low of 1.5 in Q4 2023.
• Average Price to Sales over 4 years is 430.44, with a median of 292.52 recorded in 2022.
• Year-over-year, Price to Sales soared 4497.72% in 2022 and slumped 100.21% in 2023.
• Over 4 years, Price to Sales stood at 719.23 in 2022, then tumbled by 100.21% to 1.5 in 2023, then soared by 21782.04% to 324.66 in 2025, then plunged by 67.55% to 105.35 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 105.35 in Q2 2026, 237.66 in Q1 2026, and 324.66 in Q4 2025.